image_pdfimage_print

Nov. 13, 2025 – Below are titles – linked to more than 100 poster abstracts – that will be presented at ASH 2025 involving researchers from Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine. The names of presenting and/or first or last authors are highlighted in bold. Also included is information on three special sessions.

The 67th-annual meeting and exposition of the American Society of Hematology will be held in Orlando, Florida, Dec. 6-9.

POSTER PRESENTATIONS (with links to full abstracts)

  1. Cost comparison of prophylactic vs. on-demand use of a 1:1 ratio pdVWF/FVIII concentrate in type 3 von willebrand disease with severe bleeding phenotype in the United States: A payer and societal perspective
  2. Monoclonal gammopathy-related coagulopathies: A systematic analysis • Dr. Tessa Lavorgna is the presenting author.
  3. Direct thrombin inhibition by paraprotein in multiple myeloma: A rare mechanism of paraprotein-mediated coagulopathy, corrected with myeloma therapy • Dr. Tessa Lavorgna is the presenting author.
  4. Emicizumab for severe von willebrand disease (VWD): The (EmiVWD) study enrollment 2025
  5. Identifying novel ‘druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML
  6. Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678
  7. Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
  8. Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy • Dr. Justin Watts is the presenting author.
  9. Results of a phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia
  10. A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS
  11. Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles • Dr. Justin Watts is the presenting author.
  12. Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders
  13. Genomic and transcriptomic landscape of extranodal marginal zone lymphoma • Dr. Izidore S. Lossos is the presenting author.
  14. A genetic comparison of epstein-barr virus-associated polymorphic lymphoproliferative disorder and diffuse large B cell lymphoma • Dr. Jennifer Chapman is the presenting author.
  15. FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis
  16. Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial
  17. Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial
  18. Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study.
  19. Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease
  20. Daratumumab with dose-adjusted EPOCH feasibility and early efficacy in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105
  21. Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study
  22. Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis
  23. Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes
  24. Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)
  25. Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation
  26. Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up
  27. A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL • Dr. Georgios Pongas is the presenting author.
  28. Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma • Researcher Ava Amidei is the presenting author.
  29. Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial
  30. Avoidance of ATG improves outcomes in double-cord blood transplantation for hematological malignancies
  31. Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial
  32. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes
  33. Relationship of sociodemographic factors to presentation and natural history of provoked venous thromboembolism in u.s. children: A secondary analysis of the multinational kids-DOTT trial
  34. Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma
  35. Ferroportin Q248H mutation is associated with the less weight loss in persons with HIV-1
  36. Automated grading of castleman disease histopathology using an attention-based multiple-instance learning model
  37. A risk-based scoring approach to individualize prophylaxis in patients with Hemophilia A: Results from the predict study • Dr. Fernando Corrales-Medina is the presenting author.
  38. Efficacy and safety of tranexamic acid in non-haemophilia bleeding disorders: A systematic review of randomized controlled trials
  39. IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease
  40. Butyrate ameliorates Tet2-deficient clonal hematopoiesis phenotypes driven by high B12-induced gut dysbiosis. • Researcher John Brabson is the presenting author.
  41. Vitamin B12 drives epigenetic reprogramming and leukemia progression through metabolic rewiring in AML • Researcher Peter Lyon is the presenting author.
  42. Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors • Researcher Mina Tayari is the presenting author.
  43. Final results of a phase I/II trial of palbociclib and CPX-351 in patients with Acute Myeloid Leukemia
  44. Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib
  45. Characterizing the biological function FOXO3 and its role as a predictive biomarker in HTLV-1 related adult T-cell leukemia-lymphoma • Dr. Georgios Pongas is the presenting author.
  46. Thyroid hormones enhance the responsiveness of T-cell lymphomas to romidepsin
  47. Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients
    treated with immunochemotherapy: Evidence from an international cohort with independent validation
  48. Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel) • Dr. Amer Beitinjaneh is the presenting author.
  49. Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study
  50. Clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study
  51. Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis • Dr. Asaad Trabolsi is the presenting author.
  52. Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients
  53. Assessing the utility of the charlson comorbidity index in predicting outcomes of CAR-T therapy in patients with diffuse large B-cell lymphoma
  54. Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study
  55. EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)
  56. Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study
  57. Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts
  58. Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS)
    validate database
  59. The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
  60. Long-read direct RNA-seq reveals dynamic MM transcriptome made of novel isoforms and post-transcriptional modifications
  61. Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma • Dr. Benjamin Diamond is the presenting author.
  62. Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden
  63. Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes • Researcher Nathan Becker is the presenting author.
  64. Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma
  65. Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing
  66. Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants • Researcher Arjun Raj Rajanna is the presenting author.
  67. A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study) • Dr. Ola Landren is the presenting author.
  68. Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study • Dr. Ola Landren is the presenting author.
  69. Assessment of prolonged thrombocytopenia after CD19 CAR-T therapy: Evidence for reduced production • Dr. Toral Shastri is the presenting author.
  70. Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study
  71. Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications
  72. Optimizing anticoagulation for hospitalized children: A single-institution pediatric anticoagulation stewardship experience • Dr. Rachel Kronenfeld is the presenting author.
  73. Identifying barriers to clinical trial enrollment for children with relapsed or refractory hematologic malignancies
  74. Understanding the menopause transition in sickle cell disease: An analysis of the implementation of the adapted menopause quick 6
  75. Real-world use of prophylaxis in people with non-severe hemophilia in the United States: Insights from the athn transcends Study – hemophilia natural history arm • Dr. Fernando Corrales-Medina is the presenting author.
  76. Age-stratified prognostic performance of patient- vs disease-related IPI factors in large Bcell lymphoma
  77. Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study
  78. Adherence to the 2018 world cancer research fund/American institute for cancer research cancer prevention recommendations and mortality among blood cancer survivors • Researcher LaShae Rolle is the presenting author.
  79. Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The life-l study • Melissa Lopez-Pentecost, Ph.D., is the presenting author.
  80. Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab • Researcher Maya Bloomberg is the first author.
  81. Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective
  82. PARP1 facilitates transcriptional activity and stability of the BCL6 protein and is a therapeutic target in BCL6 expressing lymphomas • Dr. Izidore S. Lossos is the presenting author.
  83. Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells
  84. Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia • Dr. Sangeetha Venugopal is the first author.
  85. A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy • Dr. Justin Watts is the presenting author.
  86. Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study
  87. Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy
  88. Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations
  89. Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma
  90. FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting
  91. Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study
  92. Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts
  93. Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP
  94. INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy • Dr. Justin Watts is the presenting author.
  95. Exposure to agent orange and risk of myelodysplastic syndromes • Dr. Mikkael Sekeres is the presenting author.
  96. Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States • Dr. Mikkael Sekeres is the presenting author.
  97. Artificial intelligence-based diagnosis of myelodysplastic syndromes/neoplasms using bone marrow
  98. Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset
  99. The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress
  100. Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.
  101. On the cellular origins of multiple myeloma
  102. High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy
  103. Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence
  104. Subclonal genomic heterogeneity shapes immune crosstalk and clinical outcomes in multiple myeloma
  105. Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM) • Dr. Michael Durante is the presenting author.
  106. The importance of MRI in diagnostic workup of smoldering multiple myeloma
  107. A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study) • Dr. Ola Landgren is the presenting author.
  108. Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings
  109. Evaluating the CAR-hematotox score in patients with refractory-relapsed multiple myeloma treated with bispecific T-cell engager therapy • Dr. Emmanuel Bugarin Estrada is the presenting author.
  110. A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results
  111. Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)
  112. Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL • Dr. Jay Spiegel is the presenting author.
  113. Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy
  114. Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematologic malignancies: Initial Results from multi-institutional first-in-human trials
  115. Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors
  116. Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes
  117. Impact of interhospital transfer on inpatient outcomes in Acute Myeloid Leukemia
  118. Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort
  119. Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series • Researcher Erica Lamkin is the presenting author.

SPECIAL SESSIONS

Post Views: 474